ALT
Altimmune IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$433.25M
P/E Ratio
—
EPS
$-1.00
Beta
0.34
52W High
$7.73
52W Low
$2.87
50-Day MA
$4.20
200-Day MA
$4.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.18
PEG Ratio
32.62
About Altimmune Inc
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | 41,000 |
| Gross Profit (TTM) | $-66.39M |
| EBITDA | $-94.38M |
| Operating Margin | -111127.00% |
| Return on Equity | -50.60% |
| Return on Assets | -28.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.03 |
| Price-to-Book | 1.93 |
| Price-to-Sales (TTM) | 10567.08 |
| EV/Revenue | 4783.73 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 420.00% |
| Shares Outstanding | $130.10M |
| Float | $129.18M |
| % Insiders | 0.59% |
| % Institutions | 42.49% |
Analyst Ratings
Consensus ($18.00 target)
3
Strong Buy5
Buy1
Hold1
SellData last updated: 4/7/2026